Sugi Predict

Sugi Predict / Compounds / SCHEMBL2652407

SCHEMBL2652407

SCHEMBL2652407

O=CNCCN1CCNC1=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ LMNA P02545 1/20 0.47
▸ KMT2A Q03164 4/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ POLB P06746 2/20 0.39
▸ MAPT P10636 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ CREBBP Q92793 1/20 0.37
▸ SCN9A Q15858 3/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ RET P07949 1/20 0.35
▸ KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4465741 0.89 KMT2A (0.43) ALDH1A1KDM4ELMNAKMT2ARAB9A
SCHEMBL471729 0.84 ALDH1A1 (0.50) ALDH1A1KDM4ELMNAKMT2ARAB9A
SCHEMBL22030392 0.82 ALDH1A1 (0.49) ALDH1A1KDM4ELMNAKMT2ARAB9A
SCHEMBL11419796 0.79 KMT2A (0.49) ALDH1A1KDM4ELMNAKMT2ARAB9A
SCHEMBL6284635 0.78 KMT2A (0.49) ALDH1A1KDM4ELMNAKMT2ARAB9A
SCHEMBL7913464 0.77 ALDH1A1 (0.43) ALDH1A1KDM4ELMNAKMT2ARAB9A
SCHEMBL13236669 0.77 ALDH1A1 (0.50) ALDH1A1KDM4ELMNAKMT2ARAB9A
SCHEMBL16588388 0.77 KMT2A (0.48) ALDH1A1KDM4ELMNAKMT2ARAB9A
SCHEMBL6284446 0.77 KMT2A (0.51) ALDH1A1KDM4ELMNAKMT2ARAB9A
SCHEMBL259671 0.76 ACE2 (0.47) ALDH1A1KDM4ELMNAKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2004-04-01 — — US claimed
US-20030216410-A1 Combination therapy for the treatment of cancer PHARMACIA CORPORATION 2003-11-20 — — US claimed
US-6573293-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. 2003-06-03 — — US claimed
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PHARMACIA & UPJOHN COMPANY LLC 2002-10-24 — — US claimed
EP-2593438-B1 MOLECULES HAVING COMBINABLE GROUPS ARKEMA FRANCE (FR) 2017-09-06 — — EP disclosed
US-7572924-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. (US) 2009-08-11 — — US disclosed
US-20080312207-A1 Compounds SYNGENTA CROP PROTECTION AG (CH) 2008-12-18 — — US disclosed
US-7320996-B2 Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer SUGEN, INC (US) 2008-01-22 — — US disclosed
US-20070010569-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2007-01-11 — — US disclosed
EP-1718625-A1 COMPOUNDS AstraZeneca AB (SE) 2006-11-08 — — EP disclosed
US-7125905-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2006-10-24 — — US disclosed
US-7053114-B2 Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives SUGEN, INC. (US) 2006-05-30 — — US disclosed
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2004-04-01 — — US disclosed
US-20030216410-A1 Combination therapy for the treatment of cancer PHARMACIA CORPORATION 2003-11-20 — — US disclosed
US-6573293-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. 2003-06-03 — — US disclosed
US-20030100555-A1 Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives SUGEN. INC. 2003-05-29 — — US disclosed
WO-2003015608-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN, INC. (US) 2003-02-27 — — WO disclosed
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PHARMACIA & UPJOHN COMPANY LLC 2002-10-24 — — US disclosed
EP-0705835-A1 Quinoxalic-2,3-diones with an oxa or thiaheterocyclic fused ring CIBA-GEIGY AG (CH) 1996-04-10 — — EP disclosed
EP-0705834-A1 Quinoxaline-2,3-diones with an azaheterocyclic fused ring CIBA-GEIGY AG (CH) 1996-04-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312207-A1 Compounds GRK4, PTGER4, GRK5 ALDH1A1 3010/4885KDM4E 1250/4885LMNA 2105/4885
US-20030216410-A1 Combination therapy for the treatment of cancer PTGS2, PTGES2, PTGFR ALDH1A1 918/4885KDM4E 2807/4885LMNA 4272/4885
US-20030100555-A1 Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives PLK2, CDK2, PDPK1 ALDH1A1 1738/4885KDM4E 1069/4885LMNA 2393/4885
US-20070010569-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, PLK2, PNCK ALDH1A1 2848/4885KDM4E 1351/4885LMNA 3259/4885
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 ALDH1A1 2793/4885KDM4E 1307/4885LMNA 3333/4885
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 ALDH1A1 2793/4885KDM4E 1307/4885LMNA 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.